Group items matching

in title, tags, annotations or url

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Also listed under R21

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

 The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research. 

To that end, CCF is accepting applications for its Global Oncology Young Investigator Award. Through the program, a single grant of up to $50,000 will be awarded to an early-career investigator in support of global oncology research. "Global oncology" as defined by the foundation implies an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world. Projects therefore need to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and/or researching the cost of creating sustainable models where they do not exist.

rants of up to $150,000 over two years will be awarded in support of projects in one or more of the following areas of lung cancer research: lung cancer biology; prevention and screening for early detection; identification of new biomarkers and the development of targeted therapies; development of more effective and less toxic therapies; supportive measures for people with lung cancer and their families; and quality of care and outcomes research. Through the program, basic, translational, and clinical research will be supported. To be eligible, investigators must be affiliated with a nonprofit academic or research institution and must fall into one of the following categories: students and fellows; young and mid-career investigators with less than ten years' experience since initial faculty appointment; non-tenure track researchers, staff scientists, and clinicians (any number years of experience). Proposals from investigators at U.S.-based and international institutions are eligible apply, regardless of residency/citizenship status.

BBCR works to advance its mission in four principal ways: supporting academic research institutions as they research tools and techniques that can increase the accuracy of and improve outcomes in biopsies and tumor removal procedures; identifying ways to improve patient outcomes and access; investing in emerging research and researchers; and serving as an active contributor to the culture of access and innovation in cancer care. To that end, BBCR is accepting applications from organizations doing breakthrough research focused on the prevention, treatment, and cures for breast and prostate cancer. Grants ranging between $5,000 and $25,000 will be awarded to teams doing research with the potential to significantly improve cancer prevention, treatment, access to, and, ultimately, a cure for breast and prostate cancer.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R21 applications for exploratory/developmental research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

The Conquer Cancer Foundation was founded by cancer doctors at the American Society of Clinical Oncology to support dramatic advances in the prevention, treatment, and cures of all types of cancer. To that end, CCF is accepting applications for its Global Oncology Young Investigator Award. Through the program, a single grant of up to $50,000 will be awarded to an early-career investigator in support of global oncology research. "Global oncology" as defined by the foundation implies an approach to the practice of oncology that acknowledges the reality of limited resources in most parts of the world. Projects therefore need to be a research exercise - identifying training models, researching their outcomes, analyzing the outcomes of those models to select the most effective curriculum, and/or researching the cost of creating sustainable models where they do not exist.

The Neuroendocrine Tumor Research Foundation (NETRF) is the largest private funder of NET research. Since 2005, NETRF has funded $22 million in scientific research to expand the molecular understanding of NETs and help drive personalized treatment options for patients.  To that end, NETRF has issued a 2019 Request for Applications (RFA) for innovative research that increases our basic understanding of these uncommon tumors and leads to the development of more effective therapies. Grants ranging from $100,000 to $1.2 million will support projects over one to four years in the areas of basic, translational, or clinical research.

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. Also listed under R01.

This announcement provides funds to recipients to partner with health systems and individual primary care clinics to implement evidence-based interventions (EBIs) to increase colorectal cancer (CRC) screening uptake among applicant defined populations age 50-75 years that have CRC screening rates lower than the national, regional, or local rate. Recipients will: 1) establish partnerships with health systems and primary care clinics to implement at least two of four EBIs recommended in The Community Guide (client reminders; provider reminders, reduction of structural barriers, and provider assessment and feedback); 2) establish partnerships with organizations that provide expertise to support the implementation of EBIs in primary care clinics; 3) conduct a formal assessment of each clinics capacity/readiness to implement EBIs; 4) utilize the clinic assessment to select appropriate EBIs to implement; 5) provide resources to partner clinics to provide and support completion of follow-up colonoscopies after a positive or abnormal screening test; and 6) collect and submit high-quality clinic-level data including baseline and annual CRC screening rates.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Also listed under R01.

The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

LIVESTRONG Cancer Institutes' mission: To rethink the full range of cancer care, from prevention to diagnosis, treatment, survivorship and end-of-life care - all with a focus on the patient's needs, values and preferences. Projects and organizations funded must also directly support the LIVESTRONG mission and the mission of the LIVESTRONG Cancer Institutes and should not be at odds with either mission.

To that end, the foundation is accepting proposals for innovative leukemia research. Grants of up to $50,000 over a year will be awarded to new and established investigators for lab, translational, or clinical research related to acute leukemia. Renewals of initial research support may be considered for one or more additional years based on productivity.

In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative with a focus on diagnostic performance improvement. The initiative aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes and save lives. The initiative's first area of focus is to develop and validate new measures for diagnostic performance. Examples of our first cohort of grants for diagnostic clinical quality measures are now available for review. Starting with measure development is important - currently, U.S. health care systems are unable to systemically measure diagnostic performance in real time, which limits the ability to quantify performance and guide improvements. 

The purpose of the FOA is to support the development of collaborative, multi-disciplinary basic research centers to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. It is anticipated that each center will use systems-level approaches that encompass chronological progression and biological scales to derive a more comprehensive and cohesive picture of metastasis. Centers may derive new physiologically relevant models that capture the entire metastatic process or develop new experimental and analytical technologies or probes for tracking and monitoring the in vivo dynamics of metastatic cell states.

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

The Mark Foundation Emerging Leader Awards support innovative research from the next generation of leaders in cancer research. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.